XML 29 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Current Liabilities
6 Months Ended
Jun. 30, 2019
Payables and Accruals [Abstract]  
Current Liabilities CURRENT LIABILITIES
Accrued expenses consisted of the following as of June 30, 2019 and December 31, 2018 (in thousands):
 
June 30, 2019
 
December 31, 2018
Commercial rebates, fees and returns
$
107,919

 
$
80,520

Milestone payment for FDA approval of Vyleesi
60,000

 
—

Professional, license, and other fees and expenses
23,663

 
23,242

Salaries, bonuses, and other compensation
16,674

 
22,482

Research and development expense
3,311

 
2,226

Interest expense
867

 
1,067

Restructuring expense
1,777

 
—

Total accrued expenses
$
214,211

 
$
129,537